Vol. 4 No. 5 (2024)
Reimbursement Recommendations

Avatrombopag (Doptelet)

decorative image of the issue cover

Published May 27, 2024

Key Messages

  • We recommend that Doptelet not be reimbursed by public drug plans for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP).
  • Evidence from 1 clinical trial showed that Doptelet improved patients’ platelet counts after 6 months of treatment; however, it is not known whether Doptelet can reduce bleeding occurrence, reduce the use of other therapies for ITP used concomitantly with Doptelet, improve symptoms, or improve health-related quality of life when compared to placebo. In addition, evidence from 1 indirect treatment comparison study showed that the comparative efficacy of Doptelet to other established treatments for chronic ITP remains unknown.
  • Patients identified a need for treatments that can reduce the risk of bleeding and improve their quality of life. However, there was not enough evidence to show that Doptelet would meet this need.